Immunological Status of Septic and Trauma Patients. I. High Tumor Necrosis Factor α Serum Levels in Septic and Trauma Patients are Not Responsible for Increased Mortality; a Prognostic Value of Serum Interleukin 6

Archivum Immunologiae et Therapiae Experimentalis

Volumn 45, Issue 2-3, 1997, Pages 169-175

  Adamik, Barbara ^a   Zimecki, Michał ^b   Właszczyk, Andrzej ^a   Kübler, Andrzej ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Interleukin 6; Sepsis; Trauma; Tumor necrosis factor

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CELL LINE; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOLOGY; INJURY; KINETICS; MALE; MIDDLE AGED; MORTALITY; MULTIPLE ORGAN FAILURE; PHYSIOLOGY; PROGNOSIS; PROSPECTIVE STUDY; REGENERATION; SEPSIS; SEPTIC SHOCK; SURVIVAL; WOUND HEALING;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CELL LINE; FEMALE; HUMANS; INTERLEUKIN-6; KINETICS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROGNOSIS; PROSPECTIVE STUDIES; REGENERATION; SEPSIS; SHOCK, SEPTIC; SURVIVAL ANALYSIS; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING; WOUNDS AND INJURIES;

EID: 0031312507     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. ABRAHAM E., WUNDERINK R. and SILWERMAN E. (1995): Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome: a randomized, controlled, double blind, multicenter clinical trial. JAMA, 273, 934 - 941.
2. AIKAWA N., SHINOZAWA Y. and ISHIBIKI K. (1987): Clinical analysis of multiple organ failure in burned patients. Burns, 13, 103 - 109.
3. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference (1992): Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit. Care Med., 20, 864 - 874.
4. BARTON R. and CERRA F. B. (1989): The hypermetabolism in multiple organ failure syndrome. Chest, 96, 1153 - 1160.
5. BAUMAN H. and GAULDIE J. (1994): The acute phase response. Immunol. Today, 15, 74 - 80.
6. BAXEVANIS C. N., PAPILAS K., DEDOUSSIS G. V., PAVLIS T. and PAPAMICHAEL M. (1994): Abnormal cytokine serum levels correlate with impaired cellular immune response after surgery. Clin. Immunol. Immunopathol., 1, 82 - 88.
7. BEAL A. L. and CERRA F. B. (1994): Multiple organ failure syndrome in the 1990s. JAMA, 3, 226 - 233.
8. BELLOMO R. (1992): The cytokine network in the critically ill. Anesth. Intensive Care, 20, 288 - 302.
9. BERNARD G. R. (1995): Sepsis trials: intersection of investigation, regulation, founding and practise. Am. J. Respir. Crit. Care Med., 152, 4 - 10.
10. BEUTLER B. (1995): TNF, immunity and inflammatory disease: lessons of the past decade. J. Invest. Med., 43, 227 - 235.
11. BEUTLER B., MILSARK I. W. and CERAMI A. C. (1985): Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science, 229, 869 - 871.
12. BIRCHER N. G. (1991): Shock syndromes: hemorrhagic and septic shock states. Curr. Opin. Anesth., 4, 224 - 228.
13. BRITIGAN B. E., HASSETT D. J., ROSEN G. M., HAMIL D. R. and COHEN M. S. (1989): Neutrophil degranulation inhibits potential hydroxyl radical formation. Biochem. J., 264, 447 - 455.
14. CALANDRA T., BAUMGARTNER J. D., GRAU D. G., WU M. M., LAMBERT P. M., SCHELLEKENS J., VERHOEF J. and GLAUSER M. P. (1990): Prognostic values of tumor necrosis factor/cachectin, interleukin 1, interferon α and interferon γ in the serum of patients with septic shock. J. Infect. Dis., 161, 982 - 987.
15. CALANDRA T., GERAIN J., HEUMANN D., BAUMGARTNER J. D. and GLAUSER M. P. (1991): High circulating levels of interleukin 6 in patients with septic shock: evolution during sepsis, prognostic value and interplay with other cytokines. Am. J. Med., 91, 23 - 29.
16. CASEY L. C., BALK R. A. and BONE R. C. (1993): Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann. Intern. Med., 119, 771 - 778.
17. CROSS A. S., SADOFF J. C., KELLY N., BERNTON E. and GEMSKI P. (1989): Pretreatment with recombinant murine tumor necrosis factor α/cachectin and murine interleukin 1 α protects mice from lethal bacterial infection. J. Exp. Med., 169, 2021 - 2027.
18. DAL NOGARE A. R. (1991): Southwestern Internal Medicine Conference: Septic shock. Am. J. Med. Sci., 1, 50 - 65.
19. DAMAS P., REUTER A., GYSEN P., DEMONTY J., LAMY M. and FRANCHIMON P. (1989): Tumor necrosis factor and interleukin 1 serum levels during severe sepsis in humans. Crit. Care Med., 17, 975 - 978.
20. DHAINAUT J. F., TENAILLON A. and LE TULZO Y. (1994): Platelet-activating factor receptor antagonist BN52021 in the treatment of severe sepsis. Randomized double-blind, placebo-controlled multicenter clinical trial. Crit. Care Med., 22, 1720 - 1728.
21. ESPEVIK T. and NISSEN-MEYER J. (1986): A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxix factor/tumor necrosis factor from human monocytes. J. Immunol. Methods, 95, 99 - 105.
22. EVANS T. J., MOYES D. and CARPENTER A. (1994): Protective effect of 55 but not 75 kD soluble tumor necrosis factor receptor immunoglobulin G fusion proteins in an animal model of Gram-negative sepsis. J. Exp. Med., 180, 2173 - 2179.
23. FISHER C. J. JR., AGOSTI J. M., OPAL S. M., LOWRY S. F., BALK R. A., SADOFF J. C., ABRAHAM E., SCHEIN R. M. H. and BENJAMIN E. (1996): Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N. Engl. J. Med., 334, 1697 - 1702.
24. FISHER C. J. JR., DUAINAUT J. F. and OPAL S. M. (1994): Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from randomized double-blind, placebo-controlled trial. JAMA, 271, 1836 - 1843.
25. GLAUSER M. P., HEUMANN D., BAUMGARTNER J. D. and COHEN J. (1994): Pathogenesis and potential strategies for prevention and treatment of septic shock: an update. Clin. Infect. Dis., 18, 205 - 216.
26. HACK C. E., DE GROOT E. R., FELT-BERSMA R. J. F., NUIJENS J. M., STRACK VAN SCHIJNDEL R. J. M., ERENBERG-BELNER A. J. M., THIJS L. G. and AARDEN L. A. (1989): Increased plasma levels of interleukin 6 in sepsis. Blood, 74, 1704 - 1710.
27. INGLOT A. D., MLOCHOWSKI J., ZIELIŃSKA-JENCZYLIK J., PIASECKI E., LEDWOŃ T. K. and KLOC K. (1996): Seleno-organic compounds as immunostimulants: an approach to the structure-activity relationship. Arch. Immunol. Ther. Exp., 44, 67 - 75.
28. LEIBOVICH S. L., PLVERINI P. J. and SHEPARD H. M. (1987): Macrophage-induced angiogenesis is mediated by tumor necrosis factor. Nature, 329, 630 - 632.
29. LIU Z., SIMPSON J. and CHEERS C (1995): Interaction of interleukin 6, tumor necrosis factor and interleukin 1 during Listeria infection. Immunology, 85, 562 - 567.
30. LŌNNERDAL B. and IYER S. (1995): Lactoferrin: molecular structure and biological function. Annu. Rev. Nutr., 15, 93 - 110.
31. MARANO M. A., FONG Y. and MOLDAWAR L. L. (1990): Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg. Gynecol. Obstet., 170, 32 - 38.
32. MARKS J. D., MARKS C. B., LUCE J. M., MONTGOMERY A. B., TURNER C. B., METZ C. A. and MURRAY J. F. (1990): Plasma tumor necrosis factor in patients with septic shock. Am. Rev. Respir. Dis., 141, 94 - 97.
33. MOSCOVITZ H., SHOFER F., MIGNOT H., BEHRMAN A. and KILPATRICK L. (1994): Plasma cytokine determinations in emergency patients as a predictor of bacteriemia and infectious disease severity. Crit. Care Med., 22, 1102 - 1107.
34. PETERSEN F., LUDWIG A., FLAD H.-D. and BRANDT E. (1996): TNF-α renders human neutrophils responsive to platelet factor 4. Comparison of PF-4 and IL-8 reveals different activity profiles of the two chemokines. J. Immunol., 156, 1954 - 1962.
35. PITTET D., RANGEL-FRAUSTO S., LI N., TARARA D., COSTIGAN M., REMPE L., JEBSEN P. and WENZEL R. P. (1995): Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med., 21, 302 - 309.
36. SALPUSA Y., ZIFF M., WELKOVICH L. and CAVENDER D. (1990): Effect of inflammatory cytokines on human endotelial cell proliferation. J. Cell. Physiol., 142, 488 - 495.
37. SILVA A. T., BAYSTON K. F. and COHEN J. (1990): Prophylactic and therapeutic effects of monoclonal antibody tumor necrosis factor α in experimental gram negative shock. J. Infect. Dis., 162, 421 - 427.
38. TRACEY K. J. (1992): TNF and other cytokines in the metabolism of septic shock and cachexia. Clin. Nutrit., 11, 1 - 11.
39. 2-terminal amino acid seqence of a T-cell-derived lymphokine with growth factor acivity for B-cells hybridomas. Proc. Natl. Acad. Sci. USA, 83, 9679 - 9683.
40. WHERRY J. C., PENNINGTON J. E. and WENZEL R. P. (1993): Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies. Crit. Care Med., 21, 436 - 440.
41. WINNEFELD K., DAWCZYNSKI H., SCHIRRMEISTER W., ADAM G., FRIEDRICH U. and HEIN S. (1995): Selenium in serum and whole blood in patients with surgical interventions. Biol. Trace Elem. Res., 50, 149 - 155.